When depression includes acute suicidal thoughts or behavior, waiting weeks for a medication response can feel overwhelming. Spravato (esketamine) offers a clinically supervised option that may provide faster improvement in depressive symptoms while a broader treatment plan is developed.
Spravato for suicidal ideation is FDA-approved for treating depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior, used alongside an oral antidepressant. However, it has not been shown to prevent suicide or reduce suicidal ideation itself, and it does not replace hospitalization when immediate safety concerns require it.
Understanding what this approval means, and what it does not mean, is an important first step before discussing whether Spravato may fit your diagnosis and care needs. The distinction becomes clearer when we look at the medication’s specific FDA-approved use.
Is Spravato Approved for Treatment of Suicidal Ideation?
Yes, but the approval is specific. Spravato (esketamine) is FDA-approved for treating depressive symptoms in adults with major depressive disorder (MDD) who have acute suicidal ideation or behavior, when used with an oral antidepressant. This makes it different from using an existing depression treatment off-label when someone is experiencing a mental health crisis. The full prescribing information is available through the DailyMed label.
The approval addresses depressive symptoms associated with MDD. It does not mean that Spravato is a stand-alone suicide-prevention treatment, and it does not replace a comprehensive safety assessment. The DailyMed prescribing information states that the effectiveness of Spravato in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. It also makes clear that treatment does not preclude hospitalization when hospitalization is clinically warranted, even if a person feels some improvement after an initial dose.
What the approval does and does not mean
For a person living with an MDD diagnosis and acute suicidal thoughts or behavior, this distinction matters. A clinician may consider Spravato as one part of a broader treatment plan for depressive symptoms. That plan may also involve an oral antidepressant, ongoing psychiatric care, safety planning, support from trusted people, and a higher level of care when needed. The appropriate next step depends on an individual evaluation, current safety concerns, medical history, and the treatment setting available.
Spravato is also not a take-home medication for this use. It is administered through a restricted program in a clinical setting, where the care team can monitor the patient after dosing. This structure helps clinicians respond to risks such as sedation or dissociation, but monitoring at a treatment appointment should never be confused with emergency care. Anyone in immediate danger should call 911 or go to the nearest emergency department. In the United States, calling or texting 988 connects people with the Suicide & Crisis Lifeline.
Understanding your treatment options
Questions about how Spravato may fit into care for depression and suicidal ideation are best answered by a qualified psychiatric team. Our guide to Spravato and Ketamine Therapy explains how these approaches differ and what treatment planning may involve. A clinical consultation can help determine whether Spravato is appropriate, or whether another level of support is needed first.
How Does Spravato Work Differently in Acute Psychiatric Crisis?
The key clinical difference is speed. Traditional antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), typically require about four to six weeks before their full effect can be evaluated. Spravato (esketamine) may begin improving depressive symptoms within 24 to 48 hours for some patients. Which can matter when suicidal thoughts are occurring alongside a major depressive disorder diagnosis.
| Spravato (esketamine) | Traditional antidepressants (SSRIs/SNRIs) | |
|---|---|---|
| Onset of action | 24 to 48 hours | 4 to 6 weeks |
| Administration setting | Clinical setting under professional supervision | Self-administered at home |
| Mechanism | NMDA receptor antagonist (glutamate pathway) | Serotonin or norepinephrine reuptake inhibition |
| Post-dose monitoring | Required (2 hours minimum) | Not required |
| Use with other antidepressants | Used alongside an oral antidepressant | Replaces or augments other medications |
These differences explain why clinicians may consider Spravato when depressive symptoms are severe and faster relief may be needed. The choice between treatment options depends on an individual evaluation, safety needs, and medical history.
A different mechanism from SSRIs and SNRIs
SSRIs and SNRIs primarily affect serotonin and norepinephrine signaling. Spravato works through a different pathway as a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptors are involved in glutamate signaling, an important communication system in the brain. By acting on this pathway, esketamine can produce changes in brain signaling more quickly than medications that rely on gradual adjustments to serotonin or norepinephrine activity.
This does not mean Spravato replaces an oral antidepressant or that it is appropriate for every person experiencing suicidal ideation. The FDA-approved use for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behavior is in conjunction with an oral antidepressant. A clinician must evaluate the person’s diagnosis, symptoms, safety needs, and treatment history before recommending a plan.
What the ASPIRE II study found at 24 hours
The ASPIRE II Phase 3 study compared esketamine with placebo, with both groups receiving standard care. At 24 hours, the mean Montgomery-Asberg Depression Rating Scale (MADRS) score improved by 15.7 points in the esketamine group, compared with 12.4 points in the placebo group. The study reported greater improvement in depression scores with esketamine at that time point. Read the ASPIRE II study.
These findings help explain why clinicians may consider a faster-acting option when depressive symptoms are severe. They do not establish that Spravato prevents suicide or eliminates suicidal thoughts, and improvement after a dose does not remove the need for hospitalization when clinically warranted. Spravato also requires supervised administration and monitoring because of risks such as sedation and dissociation. If you are comparing approaches for depression with suicidal thoughts, this overview of depression with suicidal thoughts treatment options may provide additional context. Anyone in immediate danger should call 911 or contact the 988 Suicide & Crisis Lifeline.
What Are the Clinical Requirements for Using Spravato in Crisis?
Spravato treatment for suicidal ideation follows a structured safety process. Because esketamine can cause sedation, dissociation, and respiratory depression, it is not a medication a patient takes independently at home. Each session takes place in an approved clinical setting with trained professionals available to monitor the patient before, during, and after administration.
REMS enrollment and supervised administration
Spravato is available only through the SPRAVATO Risk Evaluation and Mitigation Strategy (REMS). This restricted program establishes safety requirements for treatment centers and clinicians. The nasal spray is administered under professional supervision, and patients cannot self-administer Spravato at home. A clinical team evaluates how the patient is responding and determines when it is safe to leave.
Two hours of observation after each dose
Patients must remain at the treatment center for observation for at least two hours after administration. During this period, the care team watches for changes in alertness, blood pressure, breathing, balance, and perception. Sedation or dissociation may affect a person’s ability to drive or make decisions, so patients should arrange transportation and plan to rest after the appointment. The team provides discharge guidance based on the patient’s response.
These safeguards are especially important during an acute mental health crisis. Spravato may be part of a broader treatment plan. But monitoring does not replace an emergency evaluation or hospitalization when a clinician believes a higher level of care is needed.
What the treatment schedule may look like
A typical initial schedule involves two Spravato sessions each week for four weeks, followed by one session each week. The exact plan can vary according to the patient’s diagnosis, symptoms, response to treatment, and clinical needs. Before beginning, a qualified provider explains the schedule, coordinates any oral antidepressant treatment, and reviews what to expect during recovery after each visit.
If suicidal thoughts feel immediate or you may act on them, call 911 or call or text 988 for the Suicide & Crisis Lifeline rather than waiting for an outpatient Spravato appointment.
Who Is a Candidate for Spravato When Suicidal Ideation Is Present?
Spravato may be considered for adults with a major depressive disorder diagnosis who are experiencing suicidal thoughts or behavior. It is used alongside an oral antidepressant as part of a broader treatment plan. Not as a stand-alone replacement for crisis care, psychotherapy, medication management, or hospitalization when those services are needed. A provider must evaluate your symptoms, safety, medical history, current medications, and treatment goals before determining whether Spravato is an appropriate option.
Because suicidal ideation can change quickly, an in-person clinical evaluation is especially important. The right next step depends on the severity and immediacy of your symptoms, the support available to you, and the level of care that can keep you safe. Spravato is not a guarantee against suicide or a substitute for emergency intervention. If you may act on suicidal thoughts or cannot stay safe, call 911 or go to the nearest emergency department. You can also call or text 988 for the Suicide & Crisis Lifeline.
What happens during the evaluation?
A Relief Mental Health provider can discuss your diagnosis, review your current treatment, and explain what Spravato care involves. This conversation is also an opportunity to ask about monitoring, scheduling, expected experiences, and other treatment options. Relief MH offers care across 12 locations in Illinois, Wisconsin, Colorado, and New Jersey, helping patients connect with services in a setting that fits their needs.
Insurance and prior authorization support
Relief Mental Health accepts most major commercial insurance plans and has dedicated specialists who manage the prior authorization process. Coverage can vary by plan, so the team can help verify benefits and explain the next steps. To learn more, visit the SPRAVATO treatment page, then schedule a clinical evaluation to discuss whether this approach may fit your situation.
If You Are in Crisis: Immediate Resources and Next Steps
If you may act on suicidal thoughts, feel unable to stay safe, or are in immediate danger, call 911 or go to the nearest emergency department. You can also call or text 988 to reach the 988 Suicide & Crisis Lifeline. Trained counselors can provide immediate support, help you make a safety plan, and connect you with local resources. You do not have to manage a crisis alone.
Once immediate safety is addressed, a structured clinical evaluation can help determine what support is appropriate. If you are exploring Spravato for suicidal ideation alongside care for a depression diagnosis, the next steps at Relief Mental Health generally include:
Request a consultation
Start by contacting Relief MH to discuss your symptoms, treatment history, current support, and safety needs. Be direct about suicidal thoughts, changes in risk, or any recent crisis so the care team can guide you toward the right level of care. Spravato is not a substitute for emergency services or hospitalization when those are needed.
Verify your insurance coverage
Relief MH accepts most major commercial insurance plans and can help with the insurance verification and prior authorization process. Coverage varies by plan, so the team can explain what information is needed and what to expect before treatment begins.
Complete a clinical evaluation
A qualified clinician will review your diagnosis, medications, treatment history, and current symptoms before making a recommendation. Spravato is administered in a supervised clinical setting, so treatment planning includes both medical oversight and an appropriate follow-up plan.
Relief MH serves patients through 12 locations across Illinois, Wisconsin, Colorado, and New Jersey. Learn more about SPRAVATO treatment or explore treatment for suicidal ideation. For broader context, read Spravato and Ketamine Therapy: Understanding Your Options for Treatment-Resistant Depression, then schedule a consultation to discuss your next step.
Frequently Asked Questions
How quickly can Spravato begin to help with depression symptoms?
Some people may notice improvement within 24 to 48 hours, although response varies and treatment is monitored over time. In the ASPIRE II study. Adults with major depressive disorder and active suicidal ideation who received esketamine had greater improvement in depression scores at 24 hours than those who received placebo. Alongside standard care (ASPIRE II study).
Does Spravato prevent suicide or replace emergency care?
No. The effectiveness of Spravato in preventing suicide or reducing suicidal ideation or behavior has not been demonstrated. It also does not replace hospitalization when a clinician determines that inpatient care is necessary (DailyMed prescribing information). If you may act on suicidal thoughts, call or text 988, or call 911 for immediate danger.
What happens during a Spravato treatment visit?
Spravato is administered through a restricted REMS program in a clinical setting under professional supervision. Because sedation, dissociation, and respiratory depression can occur, patients must be observed for at least two hours after each dose. It is not a medication you self-administer at home (DailyMed prescribing information).
How can I find out whether Spravato may be appropriate for me?
A psychiatric evaluation is the appropriate next step. The clinical team will review your depression diagnosis, current symptoms, treatment history, safety needs, and other medications rather than relying on a checklist alone. Relief Mental Health accepts most major commercial insurance plans and has specialists who help manage prior authorization. Schedule a consultation to discuss your options.
Schedule a Consultation About Spravato
If suicidal thoughts are affecting your daily life, a clinical conversation can help you understand your options and determine whether Spravato may fit your treatment plan. Relief Mental Health supports people across Illinois, Wisconsin, Colorado, and New Jersey with individualized care. Schedule a consultation to discuss whether Spravato for suicidal ideation may be right for you.
